Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00914641 · ClinicalTrials.gov registry record · Phase 1
Bioavailability Study Comparing Modified Release To Immediate Release Apixaban Tablets In Healthy Volunteers
A Phase 1 study of Thrombosis, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT00914641: Completed Phase 1 study of Thrombosis, sponsored by Pfizer.
NCT00914641 is a Phase 1 study of Thrombosis that has completed, run by Pfizer. The registered enrollment target is 16 participants, below the 470-participant average among 28 other Thrombosis trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00914641, a Phase 1 study of Thrombosis, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
To estimate the pharmacokinetics of apixaban when administered as three different modified release formulation tablets relative to that when apixaban is administered as an immediate release tablet
Conditions Studied
Interventions
- DRUG Apixaban IR
- DRUG Apixaban MR1
- DRUG Apixaban MR2
- DRUG Apixaban MR3
Study Locations (1)
Connecticut
- Pfizer Investigational Site - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2009-06 |
| Est. Completion | 2009-08 |
| Phase | Phase 1 |
What the finished NCT00914641 record still lists
NCT00914641 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 470-participant average among 28 other Thrombosis trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Thrombosis appearing as the primary indexed condition, and to 4 interventions - of which Apixaban IR is the first listed.
NCT00914641 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT00914641 about?
NCT00914641 is a clinical study titled "Bioavailability Study Comparing Modified Release To Immediate Release Apixaban Tablets In Healthy Volunteers". To estimate the pharmacokinetics of apixaban when administered as three different modified release formulation tablets relative to that when apixaban is administered as an immediate release tablet
What is the current status of trial NCT00914641?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2009-06. Estimated completion is 2009-08.
What conditions does trial NCT00914641 study?
This clinical trial studies the following conditions: Thrombosis.
What interventions are being tested in trial NCT00914641?
The interventions under investigation include: Apixaban IR (DRUG), Apixaban MR1 (DRUG), Apixaban MR2 (DRUG), Apixaban MR3 (DRUG).
Who is sponsoring clinical trial NCT00914641?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00914641 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thrombosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00914641's enrollment target sits among peer trials
16 23rd of 28 higher than 5 of 28 other Thrombosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Thrombosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Positron Emission Tomography (PET) Imaging of Thrombosis
RECRUITING · Phase 1
-
Pharmacokinetic and Metabolism of [14^C] BMS-986177 in Healthy Male Participants
COMPLETED · Phase 1
-
Reversibility of Apixaban Anticoagulation With the Four Factor Prothrombin Complex Concentrate Kcentra
COMPLETED · Phase 1
-
A Study to Evaluate the Safety and Pharmacokinetics of BMS-986177 in Participants With End-stage Renal Dysfunction on Chronic Stable Hemodialysis Treatment
COMPLETED · Phase 1
-
Evaluate Pharmacokinetics and Safety of BMS-986177 in Participants With Normal Renal Function and With Moderate or Severe Renal Impairment
COMPLETED · Phase 1
-
Safety and Tolerability Study of E-WE Thrombin in Healthy Adult Subjects
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia